The National Cancer Institute reports an estimated 3300 new cases and 1490 deaths in 2016, due to bone cancer in the U.S. The survival rate of bone cancer, however, has improved over the past few years, with a strong drug pipeline for bone cancer treatment. The market is expected to witness a lucrative growth throughout the forecast period.
Global Bone Cancer Treatment - Market Dynamics
The report details several factors driving and restraining the market, some of which are discussed below.
Rapidly aging population
Increased usage of combination therapies
High cost of treatment
Less awareness about effective treatment strategies
The global bone cancer treatment market has been segmented by type of treatment and end-users. The treatment segment is further segmented into surgery, chemotherapy (Doxorubicin, Cisplatin, Carboplatin, Etoposide, Ifosfamide, Cyclophosphamide, Methotrexate, Vincristine), radiation therapy and targeted therapy (Imatinib, Denosumab). The end-user segment consists of multispecialty hospitals and cancer research institutes. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.
Major Companies in the Sector Include:
This Report Offers:
Market definition, along with identification of key drivers and restraints for the market.
Market analysis with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.
An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2. RESEARCH METHODOLOGY
2.2 Analysis Methodology
2.3 Study Timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW AND INDUSTRY TRENDS
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porters Five Force Analysis
5.3.1 Bargaining Power Of Suppliers
5.3.2 Bargaining Power Of Buyers
5.3.3 Degree Of Competition
5.3.4 Threat Of Substitution
5.3.5 Threat Of New Entrants
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 Market Drivers
6.1.1 Rapidly Aging Population
6.1.2 Increased Usage of Combination Therapies
6.2 Market Restraints
6.2.1 High Cost of Treatment
6.2.2 Less Awareness About Effective Treatment Strategies
6.3 Market Opportunities
6.4 Key Challenges
7. Global Bone Cancer Treatment Market - Segmentation
7.1 BY TYPE OF TREATMENT
184.108.40.206 Limb Savage Surgery
220.127.116.11 Reconstructive Surgery
7.1.3 Radiation Therapy
7.1.4 Targeted Therapy
7.2 By End-User
7.2.1 Multispecialty Hospitals
7.2.2 Cancer Research Institutes
8. Global Bone Cancer Treatment Market - Regional Shares and Forecast
8.1 North America
8.1.1 United States
8.2.5 Spain & Portugal
8.2.8 Rest of Europe
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 The Middle East and Africa
8.4.2 South Africa
8.4.3 Rest of the Middle East and Africa
8.5 Latin America
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Novartis AG
10.3 F. Hoffmann-La Roche Ltd.
10.5 Merrion Pharmaceuticals Plc.
10.7 Genta Incorporated
10.8 Galapagos NV
10.9 Catena Pharmaceuticals Inc.
10.10 Digna Biotech S.L.
10.11 Medivir AB
10.12 Amura Holdings
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market